HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Tate, J. R. Articles by Hickman, P. E. Search for Related Content PubMed PubMed Citation Articles by Tate, J. R. Articles by Hickman, P. E. Related Collections Proteomics and Protein Markers

Reporting of Cardiac Troponin Concentrations

¹ Department of Chemical Pathology, Queensland Health Pathology Service, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD 4102, Australia

² Department of Biochemistry, Sullivan Nicolaides Pathology, Indooroopilly, QLD 4068, Australia

³ Roche Diagnostics Australia, Castle Hill, NSW 2154, Australia

⁴ Department of Chemical Pathology, Queensland Health Pathology Service, The Prince Charles Hospital, Chermside, QLD 4032, Australia

^aAuthor for correspondence. Fax 61-73-240-7070; e-mail jill_tate@health.qld.gov.au.

The first 20% of the full text of this article appears below.

To the Editor:

There is currently substantial debate about how cardiac troponin concentrations should be reported. We would like to offer an alternative strategy to two recent recommendations.

In a recent editorial, Apple and Wu (1) proposed that the concentration of cardiac troponin that corresponds to an analytical imprecision (CV) of 10% be used as a medical diagnostic guide.

Panteghini et al. (2), in their document on quality specifications for cardiac troponin assays, state that "the detection limit ... of cardiac troponin ... should be significantly lower than the clinical discrimination limit used". The main reason for this is that patient risk stratification based on results generated by assays not meeting this requirement would be compromised by considerable imprecision.

In contrast, a recent article on the proposed new definition of myocardial infarction states that "A review of currently available data demonstrates no discernible threshold below which an increased value for cardiac troponin would be deemed harmless" (3). Thus, the first two views (1)(2) focus on ensuring that reported results are real, and the third (3) is intent on extracting the maximum clinically useful information. Is it possible to reconcile these imperatives?

Current commercially available assays for cardiac troponin cannot detect the picomolar concentrations of protein that are reportedly present in the blood of healthy persons (4). This point is supported by recent work from Roche Diagnostics in their efforts to establish a reference value for cardiac troponin T. Among 1951 apparently healthy persons, only 19 had troponin T concentrations above the minimum detectable concentration of 0.010 . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				M. Panteghini, F. Pagani, K.-T. J. Yeo, F. S. Apple, R. H. Christenson, F. Dati, J. Mair, J. Ravkilde, and A. H.B. Wu Evaluation of Imprecision for Cardiac Troponin Assays at Low-Range Concentrations Clin. Chem., February 1, 2004; 50(2): 327 - 332. [Abstract] [Full Text] [PDF]

				J. H.C. Diris, C. M. Hackeng, J. P. Kooman, Y. M. Pinto, W. T. Hermens, and M. P. van Dieijen-Visser Impaired Renal Clearance Explains Elevated Troponin T Fragments in Hemodialysis Patients Circulation, January 6, 2004; 109(1): 23 - 25. [Abstract] [Full Text] [PDF]